Agenus shared on LinkedIn:
“Agenus today reported third quarter 2026 financial results and highlighted progress toward initiation of ROBBIN, its planned global Phase 3 trial to evaluate BOT+BAL in neoadjuvant colon cancer.
ROBBIN is supported by recently published clinical findings from the NEST and UNICORN studies.
Additional updates included the first marketing authorizations for BOT+BAL in Armenia and financing aligned with upcoming development milestones.”
Press Release
Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study
- ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engagement advances preparations across the Americas, Europe and Asia
- Peer-reviewed NEST and UNICORN manuscripts report approximately 30% pathologic complete responses with short-course BOT+BAL MSS colon cancer; no recurrences at median follow-up of 23.5–32.2 months in NEST and 19.2 months in UNICORN
- First marketing authorizations for BOT+BAL granted in Armenia
- $17.0 million in year-to-date pre-commercial product revenue from global patient access programs
- Positive operating income for third consecutive quarter; $86.9 million in cash, cash equivalents and short-term investments, with milestone-aligned financing supporting ROBBIN’s development and corporate operations through 2031
You can also read:
Armenia Grants World’s First Marketing Authorizations for BOT+BAL in MSS mCRC
Inside the ROBBIN Phase 3 Strategy: Bringing BOT+BAL Into the Neoadjuvant Setting
UNICORN Challenges Immunotherapy Resistance in MSS Colon Cancer
